Did the FDA legalize peptides?

On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee met to consider whether certain bulk drug substances should be included on the list of substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act — the 503A Bulks List.

FDA's own questions document for the meeting puts fourteen separate votes to the committee: for each substance, one vote on the free base and one on the acetate. The question in every case was the same — should this substance be placed on the list?

Seven substances were on that agenda, not six. Emideltide, also referred to as delta sleep-inducing peptide or DSIP, was put to the same votes as the other six. Accounts that describe six substances are describing the reported outcome rather than what was tabled.

The use a substance is reviewed for is not the use it is marketed for, and on this agenda the two frequently diverge. FDA published the pairings; they are reproduced here exactly as the agency listed them.

BPC-157 is a useful illustration. It is marketed almost entirely for recovery and tissue repair, and the use FDA formally evaluated was ulcerative colitis. A favourable view of the second is not a finding about the first.

FDA's own description of the arrangement is unambiguous: advisory committees make non-binding recommendations to the agency. They provide independent expert advice. They do not make law, they do not amend a list, and the agency is not required to follow them.

The 503A Bulks List is amended through notice-and-comment rulemaking. That is a formal process with published proposals and a public comment period, and it is the only route by which a substance actually arrives on the list. A committee vote is an input to that process, not a substitute for it.

So the sequence between a favourable vote and lawful compounding runs: the committee advises, FDA decides whether to propose a rule, a proposed rule publishes for comment, comments are considered, and a final rule may follow. Each of those steps can end differently from the one before it. One trade analysis of the meeting put the realistic span at eight to twelve months before any of it produces unambiguous legality, and that estimate assumes the process runs to completion at all.

The decisive check is the list itself. As at 2026-08-23, none of the seven substances appears on FDA's 503A Bulks List. Not BPC-157, not KPV, not TB-500, not MOTs-C, not Emideltide, not Epitalon, not Semax. The list is published by FDA and linked in the sources below; you can confirm this yourself in about a minute, and it is worth doing rather than taking our word for it.

Nor is there an FDA peptide ban, which is the other thing people arrive here looking for. There is no single instrument that bans or permits peptides as a class. FDA operates an interim policy that sorts substances nominated for compounding into three categories, and several heavily marketed peptides sit in the category the agency uses for substances it has identified as presenting significant safety risks. That is a category assignment, not a prohibition, and it is made per substance.

Status is stated per compound and never per category. Two peptides sold side by side on the same clinic menu can sit in completely different places, and the only reliable method is to look up the specific compound rather than reason from the word peptide.

FDA has published no minutes, no summary and no transcript for this meeting. Its 2026 meeting-materials index links only the meeting page, and every document there is pre-meeting: the briefing packages, the draft questions, the agenda, the roster and the webcast details. There is, at the time of writing, no primary record of how any vote went.

Trade coverage of the meeting reported that six of the seven substances received an affirmative recommendation and that Emideltide did not. Two such reports are cited below and both were retrieved and checked. We are not reproducing the vote margins, because the reports we verified do not agree with each other on at least one of them, and a tally we cannot reconcile is not a fact we should be handing you.

What survives that caution is the part that matters anyway. Whatever the margins were, a recommendation is non-binding and the list is unchanged.

Five of the seven have no dedicated page on this site, and that is deliberate rather than an omission we intend to fix. Everything we can currently source about each one is the same three facts: it was put to a vote on a stated date, FDA evaluated it for a stated use, and it is not on the 503A Bulks List. Five near-identical pages differing only by a swapped name would tell you nothing this section does not.

• KPV — evaluated for wound healing and inflammatory conditions. Not on the list.
• MOTs-C — evaluated for obesity and osteoporosis. Not on the list.
• Emideltide (DSIP) — evaluated for opioid withdrawal, chronic insomnia and narcolepsy. Not on the list, and the one substance trade coverage reported as not receiving a favourable recommendation.
• Epitalon — evaluated for insomnia. Not on the list.
• Semax — evaluated for cerebral ischemia, migraine and trigeminal neuralgia. Not on the list.

If any of these acquires a distinct regulatory history — a proposed rule naming it, a listing decision, an enforcement action — it earns its own page at that point. A vote it shares with six others is not a distinct history.

FDA has announced a further meeting of the same committee before the end of February 2027. The agenda names five more bulk drug substances being considered for the 503A Bulks List: Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, and pegylated Mechano Growth Factor (PEG-MGF).

The time and location are not yet set and FDA has said it intends to publish a Federal Register notice establishing a docket for public comment. If you have a stake in any of those five, the docket is the formal route to be heard, and it opens before the meeting rather than after it.

Expect the same pattern of coverage afterwards, and the same gap between a vote and a change in the law. A recommendation on any of those five would leave their status exactly where the July votes left the first seven.

How we verify providers

The practical use of everything above is as a test you can apply to a sales claim. A seller describing any of these compounds as newly legal, newly approved, or cleared by FDA is describing something that has not happened.

• Ask which specific compound, by name, rather than accepting "a peptide protocol".
• Ask what its status is on the 503A Bulks List, and check the answer against FDA's published list yourself.
• Ask which pharmacy prepares it, in which state, and under what authority.
• Ask what a favourable advisory vote changed about its legal position — the correct answer is nothing yet.
• If you compete under a testing body, check the current prohibited list directly, because the consequences fall on you rather than on the clinic.

We do not sell peptides, we do not prescribe, and we have no commercial relationship with anyone who does. Whether any compound is appropriate for you is a question for a licensed provider who has assessed you, and dosing is determined by that provider.

• FDA — July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — retrieved 2026-08-23
• FDA — PCAC July 23-24, 2026 meeting: Questions put to the committee — retrieved 2026-08-23
• FDA — PCAC July 23-24, 2026 meeting agenda — retrieved 2026-08-23
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — retrieved 2026-08-23
• FDA — Early Announcement for Meeting of the Pharmacy Compounding Advisory Committee — retrieved 2026-08-23
• FDA — Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks — retrieved 2026-08-23
• Pharmaceutical Executive — FDA Panel Votes to Loosen Restrictions for Four Peptides — retrieved 2026-08-23
• Boesen & Snow Law  The Peptide Vote Heard Round the Compounding World — retrieved 2026-08-23